Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants Oct 2, 2023
Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia Sep 18, 2023
Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing Sep 11, 2023
Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing Sep 5, 2023
Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update Aug 14, 2023
UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update May 4, 2023
Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update May 4, 2023